0001213900-26-050904
SEC filingProfusa, Inc. is a clinical-stage digital health company developing biointegrated biosensors for real-time monitoring of tissue oxygen and glucose; it has no commercial revenue in the U.S., relies on regulatory approvals (FDA PMA/De Novo), and is conducting this resale registration to facilitate capital access via a $100M committed equity facility with Ascent.
Profusa, Inc. is a pre-commercial, clinical-stage medical device company pioneering biointegrated biosensors designed to monitor tissue oxygen and glucose continuously for months—not days—via minimally invasive subcutaneous injection. Its first product, Lumee Oxygen, has CE Mark approval in the EU but remains unapproved by the FDA; Lumee Glucose has not yet been authorized for sale anywhere. The company operates with no U.S. revenue, reporting a $35.8 million net loss in 2025 and holding just $1.8 million in cash—triggering an explicit going-concern qualification from its auditor and prompting urgent capital-raising efforts. This S-1/A filing does not raise new capital for Profusa directly; instead, it registers 179.3 million shares for resale by selling stockholders—including 150.6 million Purchase Shares under a $100 million committed equity line of credit (ELOC) with Ascent Partners Fund LLC. While Profusa retains full discretion over drawdown timing and pricing, the ELOC imposes strict constraints: a 9.99% beneficial ownership cap, a $0.111–$0.14 floor price during a limited Modification Period, and mandatory Nasdaq stockholder approval for issuances exceeding 19.99%. Critically, Profusa receives no proceeds from the resale of these registered shares—only from future draws under the ELOC itself, which it expects to use for working capital and general corporate purposes. The company’s financial fragility is compounded by regulatory uncertainty: both core products face high-hurdle FDA pathways—PMA for Class III devices—with no assurance of approval timelines or outcomes. Meanwhile, Profusa confronts active delisting risk from Nasdaq, having failed to cure deficiencies in minimum bid price, market value of listed securities, and market value of publicly held shares by statutory deadlines. Its competitive differentiation rests on sensor longevity (up to 9 months for glucose), ease of deployment (hypodermic needle vs. surgery), and cost structure—but it competes against entrenched giants like Abbott, Dexcom, and Medtronic, none of whom face comparable liquidity or listing pressures. Leadership includes seasoned life sciences executives—CEO Ben Hwang (ex-Life Tech), CFO Fred Knechtel (ex-Interpace, DiamiR), and CSO Bill McMillan (co-founder of Cepheid)—yet governance risks persist, including material weaknesses in internal controls over financial reporting and reliance on related-party debt. With $14.5 million in near-term contractual obligations and no path to profitability in sight, Profusa’s viability hinges entirely on successful regulatory milestones, execution of its ELOC, and securing additional financing—making this offering a critical liquidity lifeline rather than a growth catalyst.